Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 6,345 Shares

Key Points

• Jonathan Allan, General Counsel of Stoke Therapeutics, sold 6,345 shares at $20.07 each, decreasing his holdings by 34.91% to a total of 11,831 shares.
• Stoke Therapeutics reported a quarterly loss of ($0.40) per share, beating analyst estimates, but revenue of $13.82 million fell short of the projected $31.51 million.
• Analysts have assigned a consensus rating of "Buy" on Stoke Therapeutics, with a consensus price target of $25.57, while researching various price targets between $22.00 and $30.00.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) General Counsel Jonathan Allan sold 6,345 shares of the firm's stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $20.07, for a total value of $127,344.15. Following the completion of the transaction, the general counsel owned 11,831 shares in the company, valued at $237,448.17. The trade was a 34.91% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jonathan Allan also recently made the following trade(s):

• On Tuesday, September 2nd, Jonathan Allan sold 14,922 shares of Stoke Therapeutics stock. The shares were sold at an average price of $20.14, for a total value of $300,529.08.
• On Friday, August 29th, Jonathan Allan sold 850 shares of Stoke Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $17,000.00.
• On Wednesday, August 13th, Jonathan Allan sold 13,712 shares of Stoke Therapeutics stock. The shares were sold at an average price of $15.00, for a total value of $205,680.00.

Stoke Therapeutics Trading Up 0.9%

STOK stock traded up $0.18 during midday trading on Wednesday, reaching $19.77. The stock had a trading volume of 1,307,730 shares, compared to its average volume of 810,410. The company's fifty day simple moving average is $14.42 and its 200 day simple moving average is $10.83. The company has a market cap of $1.08 billion, a price-to-earnings ratio of 23.26 and a beta of 1.14. Stoke Therapeutics, Inc. has a 52-week low of $5.35 and a 52-week high of $20.45.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. The company had revenue of $13.82 million for the quarter, compared to analyst estimates of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. Sell-side analysts predict that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on STOK shares. Jefferies Financial Group started coverage on Stoke Therapeutics in a report on Friday, July 18th. They set a "buy" rating and a $30.00 price target on the stock. BTIG Research set a $28.00 price target on Stoke Therapeutics and gave the stock a "buy" rating in a report on Monday, August 18th. Wedbush lifted their price target on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a report on Wednesday, August 13th. HC Wainwright reduced their price target on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Finally, Cantor Fitzgerald upgraded Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Two research analysts have rated the stock with a Strong Buy rating and seven have given a Buy rating to the company. Based on data from MarketBeat, Stoke Therapeutics has a consensus rating of "Buy" and a consensus price target of $25.57.

Institutional Trading of Stoke Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of STOK. Wells Fargo & Company MN increased its stake in Stoke Therapeutics by 51.2% during the fourth quarter. Wells Fargo & Company MN now owns 16,786 shares of the company's stock worth $185,000 after purchasing an additional 5,682 shares during the period. Invesco Ltd. purchased a new stake in Stoke Therapeutics during the fourth quarter worth about $133,000. Dimensional Fund Advisors LP increased its stake in Stoke Therapeutics by 103.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 538,900 shares of the company's stock worth $5,943,000 after purchasing an additional 273,890 shares during the period. Tower Research Capital LLC TRC increased its stake in Stoke Therapeutics by 70.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock worth $132,000 after purchasing an additional 4,918 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in Stoke Therapeutics by 6.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company's stock worth $414,000 after purchasing an additional 2,215 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.